MELLARIL
LOE ApproachingNDAORALCONCENTRATEPriority Review
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MELLARIL is an oral concentrate small-molecule antipsychotic approved in 1962 by Novartis. The drug's specific mechanism of action and approved indications are not documented in available data. This is a legacy product with a 60+ year market history.
LOE Approaching
Mature asset with minimal commercial investment; team size likely stable or declining as product approaches loss of exclusivity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MELLARIL offers limited career growth or visibility as a legacy asset in LOE phase with zero linked job postings. Roles on this product focus on operational excellence, compliance, and cost management rather than innovation or market expansion.
Brand ManagerField Sales Representative
Worked on MELLARIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.